

Exploring the Current and Future Role of B-Cell Maturation Antigen-Directed Therapy in the Management of Multiple Myeloma (Faculty Presentations)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Updated analysis presented at ASH 2021 from the Phase II KarMMa study evaluating idecabtagene vicleucel in patients with relapsed/refractory (R/R) multiple myeloma (M/M) demonstrated a median overall survival of approximately how many months?
 - a. 3 months
 - b. 6 months
 - c. 12 months
 - d. 24 months
2. Which of the following toxicities was most commonly reported in the DREAMM-2 study with belantamab mafodotin (2.5 mg/kg) in patients with MM?
 - a. Diarrhea
 - b. Hypercalcemia
 - c. Respiratory infection
 - d. Keratopathy
3. Which of the following best represents the approximate percentage of patients in clinical trials who have experienced significantly worsening vision with belantamab mafodotin?
 - a. <10%
 - b. 10%
 - c. 25%
 - d. 50%
4. Which of the following treatment-emergent adverse events was most common in patients with R/R MM who received elranatamab as part of the MagnetisMM-1 trial?
 - a. Anemia
 - b. Cytokine release syndrome
 - c. Neutropenia
 - d. Fatigue
5. Which of the following bispecific antibodies does NOT target B-cell maturation antigen?
 - a. Teclistamab
 - b. REGN5458
 - c. Talquetamab
 - d. Elranatamab